Consilium Strategic Communications 8th Annual Healthcare Virtual Conference

Clive Cookson has worked in science journalism for the whole of his professional life. He graduated with a First Class degree in chemistry from Oxford University in 1974. After journalism training on the Luton Evening Post, he became science correspondent of the Times Higher Education Supplement in London and then spent four years in Washington as American Editor of THES. He returned to London in 1981 as technology correspondent of the Times and moved to BBC Radio as science correspondent in 1983. He joined the Financial Times as technology editor in 1987 and has been Science Editor of the FT since 1991. He is an honorary member of the British Science Association and the American Academy of Arts and Sciences.

Mary-Jane co-founded Consilium Strategic Communications in July 2013 having led the management buy-out from M:Communications. She has more than 20 years of healthcare experience from leading communications agencies and the pharmaceutical industry and is an expert in financial, corporate, investor and scientific communications. Prior to founding Consilium, Mary-Jane established and led M:Communications’ international healthcare team where she advised public and private companies across all sub-sectors of healthcare and including some of the sector’s leading industry bodies. She has advised on a wide range of high profile IPOs, financings, M&A transactions and industry deals, crisis communications, clinical data findings and product launches. Mary-Jane worked both as a scientist and in the communications and IR team at PowderJect Pharmaceuticals plc for six years and was previously with Bell Laboratories Inc in Madison, Wisconsin, US. Mary-Jane has a BSc (Hons) in BioMedical Sciences.

Amber is a healthcare communications specialist and co-founder of Consilium Strategic Communications. Amber has extensive experience in providing strategic communications support to some of the healthcare sector’s leading companies and has delivered successful PR campaigns, including significant sector IPOs, M&A and public and private fundraisings, across Europe and North America. Prior to founding Consilium, Amber was a member of M:Communications’ healthcare team and the Pharma & Biotech team at Citigate Dewe Rogerson. Amber also has a strong background in public affairs and lobbying, with experience from the European Parliament in Brussels, the United States Senate in Washington and work for the UK's BioIndustry Association. Amber has a degree in International History and Politics from Leeds University and a Masters Degree in War Studies from Kings College London.

Hugo Fry is Managing Director of Sanofi UK, the 6th largest pharmaceutical company in the UK. He is also UK General Manager of Sanofi Pasteur, Sanofi’s vaccines business unit, and a member of the Board of Management of the Association of the British Pharmaceutical Industry (ABPI), the trade association for over 120 companies selling prescription medicines. He is currently the Board sponsor for both vaccines and the Prescription Medicines Code of Practice Authority (PMCPA). Prior to assuming this role, Hugo has held central strategic positions and commercial operational roles, leading vertically integrated teams from Drug Discovery through Clinical Development, Regulatory Affairs, Market Access, Industrial Affairs, Medical Affairs and Commercialisation. Most recently he was the Chief Marketing Officer for Sanofi Pasteur MSD (SPMSD), leading the commercial effort for the European vaccine Joint Venture. Hugo joined Aventis UK in 2003 as Head of Commercial Excellence. From 2007, Hugo spent four years in Russia leading Sanofi’s Diabetes, Oncology, Cardiovascular, Internal Medicine and Consumer Healthcare businesses, where he was also responsible for the acquisition and set up of an insulin manufacturing facility. Following a strategic acquisition, he was then appointed General Manager of Zentiva Russia, where he was instrumental in maintaining Zentiva as one of the fastest growing companies in Russia while integrating into the Sanofi Group. Hugo then joined the Sanofi Diabetes Leadership Team as Global project Leader for the lixisenatide family, heading R&D, Industrial affairs and commercial operations before assuming his role at SPMSD. Hugo holds a B.Sc. in Chemistry from the University of Salford and Studied Finance at London Business School.

George is an entrepreneur dedicated to bringing about positive change in society with particular focus on health and wellbeing. George’s early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science. His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks’ Non-Executive Chairman.

Nicola has developed a practice specialising in advising life sciences companies and other clients whose businesses have a significant reliance on intellectual property. Many of the transactions on which Nicola works have a significant international element, with parties in the US or Europe. She has particular expertise advising clients at all stages of development, from early stage startups to listed companies, and on mergers and acquisitions, joint ventures and equity fundings. Nicola’s practice also includes advising on general commercial matters such as materials transfer agreements, intellectual property licences, research & collaboration and distribution & manufacturing agreements.

Ms. Mears is a partner with Jeito Capital and has over 20 years of transactional, operational, and legal experience in biotechnology and pharma companies. She led Strategy and International Business Operations at Forest Laboratories, where she worked on the successful development and commercialization of over 10 FDA approved drugs, including Lexapro®, Namenda®, Linzess®, Vraylar® and AvyCaz® and spearheaded the company’s integration with Allergan (then known as Actavis). She also served as Chief Business Officer and General Counsel at Modern Meadow, a biotechnology company focused on sustainable materials and as Senior Counsel, Chief of Staff to PepsiCo’s General Counsel. Ms. Mears began her career as a patent attorney first with Morrison & Forester and later Kirkland & Ellis, specializing in complex intellectual property strategy and litigation. She serves on the Board of Trustees at Hackley School. Ms. Mears received her B.S. degree with honors in chemistry from Stanford University and her J.D. degree from NYU School of Law and is admitted to the US Patent Bar.

Nicholas has over 20 years’ experience in the Healthcare industry, having originally trained as a medical doctor at Cambridge University and Harvard Medical School, following an undergraduate degree in Medical Sciences with a focus on immunology also at Cambridge. He joined Morgan Stanley’s Healthcare Investment Banking Team in 2006, where he worked on a number of M&A and capital markets transactions. In early 2011, Nicholas moved to the Equity Capital Markets team at Jefferies in London, where he initially focused on raising equity capital across industries within the broader EMEA region. In December 2013, Nicholas was named as one of the Top 40 Under 40 Rising Stars in Investment Banking by Financial News, partly in recognition of the more than 20 equity capital markets transactions he completed in 2013 alone. Since mid-2013, Nicholas focused on raising equity capital for European healthcare companies, especially those companies in the biopharma subsector targeting investment from U.S.-based healthcare specialist investors. In January 2018, Nicholas moved to Stifel as a Managing Director on the Healthcare Investment Banking team to continue to focus on delivering equity financing solutions to Europe-based healthcare companies, but also with a broader remit across M&A and strategic advice. Nicholas has an especially busy practice helping UK and European companies IPO or dual list on the NASDAQ exchange.

Sean Ruby joined Citi Depositary Receipt Services in London in 2008 with responsibility for Western Europe and CEEMEA and in January 2017 was promoted to EMEA DR Sales Head. Since 2013, Sean has managed the ADR IPOs for Adaptimmune Therapeutics, Autolus Therapeutics, Bicycle Therapeutics, Calliditas Therapeutics, Cellectis, Celyad Oncology, COMPASS Pathways, DBV Technologies, Freeline Therapeutics, Galapagos, GW Pharmaceuticals, Nightstar Therapeutics, NuCana, Orchard Therapeutics, Renalytix AI, Stealth BioTherapeutics, Verona Pharma and most recently Abcam. Sean has also been responsible for the implementation/transition of ADR programmes for Addex Therapeutics, Amryt Pharma, ANGLE, Mereo BioPharma, Orexo, Realm Therapeutics and Teva Pharmaceuticals.

Josh Schimmer is a Senior Managing Director on Evercore ISI’s Biotech team, focusing on small, mid, and select large-cap biotechnology companies. Dr. Schimmer was ranked #1 in Institutional Investor’s All America Research Team for SMID Biotech in both 2018 and 2019 was runner up in 2015 and 2016. Dr. Schimmer has 14 years of biotechnology research experience, previously at Piper Jaffray, Lazard Capital Markets, Leerink Partners, and Cowen & Company. In addition, he spent two years on the buy side at Davidson Kempner. Dr. Schimmer received his Medical Degree and subspeciality training in Internal Medicine and Rheumatology from the University of Toronto and a Master’s of Business Administration from Harvard Business School.

Linden Thomson leads investment in the AXA IM Framlington Biotech Fund and supports the wider team in her role as Co-Head Global Equities at AXA IM Framlington. She has nearly two decades of buy-side and sell-side experience as one of the early specialists in the biotechnology sector. Her formative career was spent with Goldman Sachs in the Global Investment Research team covering healthcare/biotechnology. Subsequently she joined a healthcare hedge fund at start-up stage, as a key member of the team that built and launched the fund. She has been at AXA IM Framlington since 2011. She holds a BSc in Biology (Medical Microbiology Hons) from the University of Edinburgh and is a CFA Charterholder.

Sukaina reported on all aspects of the global pharmaceutical and biotechnology sector for more than 16 years before joining Consilium. Her most recent role was Managing Editor of European Commercial News at industry stalwarts Scrip and The Pink Sheet. Sukaina has a PhD in Biochemistry & Molecular Biology from UCL and a Bachelor's degree in Applied Biochemistry from Brunel University, which involved laboratory-based research placements in both the US and UK. She has appeared on TV and radio to commentate on industry strategy and has chaired panels at various industry events.

Anne has held a range of roles in drug development across multiple therapeutic areas, including oncology, neuroscience and infectious diseases. She has led the development of multiple late-phase opportunities and has led teams in successfully submitting and achieving new drug approvals for several new medicines. Anne has also had roles leading early phase drug development and patient tailoring in oncology. Her current and past responsibilities include global leadership and direction of several significant change transformations resulting in improved speed, efficiency and increased organizational health. Most notably, Anne has led Lilly’s effort to speed drug development, from target identification through successful launch. Anne served most recently as vice president of Portfolio Management, Chorus and Next Generation Research and Development, with previous roles of vice president of Oncology Clinical Development and chief operating officer for oncology. She has over 25 years of experience in the pharmaceutical industry. Anne also has experience in small-company pharma, having founded and led a startup company in oncology drug development, collaborating with the Moffitt Cancer Center and the National Cancer Institute. Anne earned a bachelor’s degree in engineering from the University of Michigan. Anne was awarded the Lilly Women’s Network Award for her efforts in mentoring and supporting women in the workplace. She was named to the first President’s Council in Lilly Research Laboratories in recognition for her leadership and impact on others.

Professor Tom Wilkinson is CSO of my mhealth, Professor of Respiratory Medicine at the University of Southampton, and Honorary Consultant at University Hospitals Southampton. He trained at the University of Cambridge and Barts and the London School of Medicine and completed his PhD at UCL studying disease mechanisms driving Infective Exacerbations of COPD. He has 20 years’ experience in health care innovation and health services research and in 2012 co-founded my mhealth with Simon Bourne. He is now a Director and Chief Scientific Officer for the company and leads the digital health research programme. Tom’s research seeks to improve outcomes for patients with long-term conditions. He currently leads several large-scale programmes of digital health implementation and appraisal across the NHS. He and his team are developing data-driven models of disease to help patients and clinicians better understand the outcome and to optimise treatment. Working with thought leaders in AI and data science the my mhealth research team is now developing the next generation of digital therapeutics. Tom has published over 100 peer-reviewed papers and reviews. His work has been recognised by National and International Awards including the European award for Innovation in Respiratory Medicine.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 70 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma Inc, and member of the board of directors of Leo Pharma and Celdara Medical. He holds M.S. and Ph.D. degrees from the University of Nijmegen.